Stock TLPH TALPHERA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Talphera, Inc.

Equities

TLPH

US00444T2096

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
0.99 USD -4.81% Intraday chart for Talphera, Inc. -11.61% +34.69%
Mar. 06 Talphera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 06 Transcript : Talphera, Inc., Q4 2023 Earnings Call, Mar 06, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Talphera: Q4 Earnings Snapshot
AQ
Talphera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Talphera, Inc., Q4 2023 Earnings Call, Mar 06, 2024
Talphera, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
AQ
Talphera, Inc. Announces Management Changes
CI
Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
PR
Talphera, Inc. Appoints Abhinav Jain to Serve as a Class II Director
CI
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition
AQ
XOMA Acquires Interest in Pain Management Medication Dsuvia for $8 Million
MT
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
PR
XOMA Corporation acquired DSUVIA® of Talphera, Inc. for $8 million.
CI
Talphera, Inc. announced that it expects to receive $16 million in funding from Nantahala Capital Management, LLC, Rosalind Advisors, Inc.
CI
AcelRx Pharmaceuticals, Inc. will Change its Ticker to TLPH from ACRX
CI
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
PR
Talphera Expects to Initiate the Registrational Study of Niyad
CI
Talphera, Inc.(NasdaqGM:TLPH) dropped from NASDAQ Composite Index
CI
AcelRx Pharmaceuticals, Inc. has Changed its Name to Talphera, Inc
CI
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States
PR
Transcript : AcelRx Pharmaceuticals, Inc. - Special Call
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TLPH Stock
  4. News Talphera, Inc.